EXSCIENTIA
21.7.2021 10:02:06 CEST | Business Wire | Press release
Exscientia , an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron） , a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved , Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI . LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 11:00:00 CEST | Press release
Enabling advertisers to prove ROI across retailers, markets, and channels with interoperable, AI-powered measurement Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-lead
Thredd Expands Partnership with ID DISTRIBUTION to Power Next Phase of Employee Benefits and Expense Innovation16.6.2026 11:00:00 CEST | Press release
Paris-based fintech will extend its card program into corporate expense management and support continued European expansion Thredd, the AI-first issuer processing platform, today announced an expanded partnership with ID DISTRIBUTIONthrough its flagship program Vaziva, a leading employee benefits and payments platform, to support its growth beyond consumer payments, into corporate payments, as well as their international expansion. Thredd has worked with ID DISTRIBUTIONsince 2020, supporting the company’s consumer offering in France with physical and digital card issuing and payments processing capabilities. Its Vaziva card program enables companies to digitally manage and distribute multiple types of employee benefits through a single prepaid Mastercard-branded card experience. The program supports convenient, secure card usage for employees to access and use benefits across categories including lunch, gifts, culture, holidays, and travel. With more employers seeking simpler, more dig
Eastnets Launches FinCrime Intelligence Platform to Unify Financial Crime Investigations16.6.2026 10:00:00 CEST | Press release
Eastnets, a global provider of compliance and payment solutions, today announced the launch of FinCrime Intelligence Platform (FCIP), a new investigation and orchestration layer that helps financial institutions unify financial crime operations, improve investigator productivity and gain a single view of risk across AML, sanctions, KYC and fraud. As financial crime operations grow in complexity, many institutions struggle with fragmented investigation tools and inconsistent workflows. FCIP addresses this challenge by providing a single, governed workspace for managing cases across compliance domains - without replacing existing detection systems. Eastnets’ FinCrime Intelligence Platform delivers centralised case management across AML, sanctions screening and KYC, structured, multi‑level investigative workflows with assistive, explainable AI to support, and not replace, human decision-making, providing full audit trails and management oversight. By consolidating AML, fraud, KYC, and scr
Respond.io Raises $62.5M Series B to Scale AI-Powered Customer Conversations Into North America and Europe16.6.2026 10:00:00 CEST | Press release
62.5M Series B led by Camber Partners, with existing investors participating. Respond.io is profitable with $35M ARR, 169% year-over-year growth, and a 30% profit margin. New capital will fund expansion into and mergers and acquisitions within North America and Europe. Respond.io, a customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors. What respond.io does Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity. The company serves industries where customers initiate conversations before buying, boo
Optimum Asset Management’s Investor Summit in Portofino brings together Mike Pompeo, Matteo Renzi and leaders across government, finance and industry to discuss the future of the global economy and geopolitics16.6.2026 09:30:00 CEST | Press release
Mike Pompeo addressed geopolitical risks including China, Iran, Ukraine and Europe-US security cooperation. Matteo Renzi, Edoardo Rixi and senior government representatives joined discussions on European competitiveness, infrastructure and energy. The summit convened institutional investors, entrepreneurs and financial market professionals to discuss the future of the global economy. The first edition of the Optimum Investors Summit – The Portofino Conversation, hosted by European real estate private equity investment firm Optimum Asset Management and its Italian partners Alberto Matta, Rodolfo Misitano, Enrico Imbraguglio and Andrea Suriano, concluded with strong participation from institutional investors (including pension funds), entrepreneurs, government representatives and financial market professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615915564/en/ Alberto Matta, Managing Partner at Optimum Asset Mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom